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The increasing number of living cutaneous melanoma patients and the increased risk of developing a second primary tumour
incited us to analyse the clinical characteristics of cutaneous melanoma and deﬁne the frequency, site, and type of second primary
cancers in cutaneous melanoma patients. We collected data on patients who visited the Department of Dermatology at the
Radboud University Nijmegen Medical Centre and were newly diagnosed with cutaneous melanoma or metastasis of melanoma
with unknown primary localization between 2002 and 2006. A total of 194 cases were included; eleven patients developed a
subsequentmelanoma,24hadatleastonebasalcellcarcinoma,threehadatleastonesquamouscellcarcinoma,and21patientshad
a second non-cutaneous primary malignancy. In conclusion, 48 patients developed a subsequent malignancy. As nonmelanoma
skin cancer is the most frequent second malignancy, our results subscribe to the necessity of follow-up by a dermatologist.
Copyright © 2009 Haike M. J. van der Velden et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
A signiﬁcant increase in the incidence of cutaneous
melanoma (CM) has been observed worldwide, leading
to a growing demand for healthcare services [1–9]. In
2003, melanoma accounted for 2869 cases of cancer in The
Netherlands. Unfortunately, incidence rates are expected to
keep rising in the future. The number of new cases in The
Netherlands is expected to be more than 4800 in 2015 [1].
Although absolute mortality rates of CM increased over the
last 40 years [2, 9], long-term survival rates are improving
[4, 7, 10], mainly due to earlier detection and improving
awareness of patients on skin changes [7, 11]. Thus, the
total number of living CM patients is increasing, ﬁxing one’s
attention to detection of metastasis, recurrence, and long-
term complications, such as second tumours.
Patients with CM have an increased risk of developing
a second primary melanoma [12–18]. Several studies also
showed a higher incidence of subsequent nonmelanoma skin
cancers (NMSCs), comprising basal cell carcinoma (BCC)
and squamous cell carcinoma (SCC), in patients with CM
in comparison with the general population [14, 17–21].
There is also a signiﬁcantly higher risk of a wide variety
of primary noncutaneous malignancies among patients with
CM [12, 14, 16–19, 21–26].
The increasing number of living CM patients and the
increased risk of developing a second primary tumour
incited us to analyse the clinical characteristics of cutaneous
melanoma and to deﬁne the frequency, site, and type of
second primary cancers in our patients.
2.MaterialandMethods
2.1. Design. We performed a historical cohort study among
patients with cutaneous melanoma at the Department of
Dermatology of the Radboud University Nijmegen (RUN)
Medical Centre (MC), The Netherlands.2 Dermatology Research and Practice
2.2. Collecting Data. We selected patients with histologi-
cally conﬁrmed ﬁrst CM or metastasis of melanoma with
unknown primary localization, diagnosed in the period
between January 2002 and December 2006. These patients
were included when visiting the Department of Dermatol-
ogy.
Clinical data were abstracted from the patients’ derma-
tology hospital charts and the Comprehensive Cancer Centre
East (IKO), covering the eastern part of The Netherlands.
Information on the patient was obtained from the electronic
patient database of our hospital up to the ﬁrst of June 2007.
Data recorded from each patient included sociodemo-
graphic and phenotypic characteristics. Furthermore, we
gathered information on family history and the occurrence
of Dysplastic Nevus Syndrome (DNS). We distinguished
two types of DNS. A familial type DNS was deﬁned as
cases of a positive family history (i.e., two or more ﬁrst-
degree relatives or three or more second-degree relatives
who suﬀered from melanoma). Individuals with melanoma,
ﬁve or more clinically atypical nevi, and a negative family
history of melanoma (ﬁrst- and second-degree relatives)
were deﬁned as sporadic type DNS [27].
Cutaneous and noncutaneous malignancies occurring
either before or after the diagnosis of CM were recorded.
The patients were considered to have a second primary
cancer when they reported it themselves or when the IKO
registered it. Contrary to the rules of the International
Agency for Research on Cancer/International Association of
Cancer Registries (IARC/IACR) [28] multiple CM arising in
thesamepatientwereincludedinourdeﬁnitionofamultiple
primary malignancy. On the other hand, we did exclude
recurrences of the melanoma.
2.3. Statistical Analysis. Statistical analysis was performed
using the Statistical Package for Social Sciences (SPSS) for
Windows (release 14.0.2). Throughout the analysis, P values
<. 05 were considered statistically signiﬁcant. For descriptive
purposes, valid percentages (percentages based on sample
size excluding missing values) were calculated. An actuarial
survivalcurvewasgeneratedusingtheKaplan-Meiermethod
for censored data.
3. Results
3.1. Clinical Data. We studied 194 cases, 90 males (46.4%)
and 104 females (53.6%); the diﬀerence between both
frequencies was not signiﬁcant (P = .3 5 1b a s e do nZ
approximation). The average age of the patients at diagnosis
of the ﬁrst CM was 51.8 years (SD 15.4) (Figure 1). We
registered 158 invasive CM, 21 in situ CM and 15 metastases
with unknown primary melanoma. The tumours were
predominantly located on the trunk, in men (42.4%) and
in women (38.5%) (Table 1). Reported symptoms on the
lesion were itch (n = 23), pain or discomfort (n = 8),
spontaneous bleeding (n = 23), and change of appearance
(n = 82). For 79 to 88 subjects, varying among these
variables,thisinformationwasmissing.Superﬁcialspreading
melanoma (SSM) was the most frequent histological type
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Figure 1: Age of the patients at the time of ﬁrst melanoma
diagnosis.
(63.9%), followed by nonspeciﬁed melanoma (8.8%) and
nodular melanoma (NM) in 8.2% of the patients. Lentigo
maligna melanoma (LMM), acral-lentiginous melanoma
(ALM), amelanotic malignant melanoma (AMM), and other
subtypes were less frequently observed (Table 1).
In Table 1 tumour thickness and invasiveness of the
primary CM are described. Median and mean tumour
thicknesses according to Breslow [29]w e r e0 . 7 5 m ma n d
1.38mm (SD 2.23), respectively. Clark invasiveness [30]w a s
available in 87.2% of the ﬁrst primary CM.
Twenty-ﬁve melanomas were associated with a dysplastic
nevus and 10 with a nevus naevocellularis. The tumour
was ulcerative in 21 patients and the same number showed
partial or complete regression. In just a few cases (n =
2) the pathologist found satellites in the ﬁrst pathological
examination.
We were able to determine the TNM stage (AJCC) [31,
32] for 172 (88.7%) ﬁrst CM: 113 (65.7%) stage I, 8 (4.7%)
stage II, 26 (15.1%) stage III, and 25 (14.5%) stage IV.
In 179 patients the localization of the primary CM was
known: they all underwent excision, and 171 were followed
by reexcision. Lymph nodes were investigated in 71 subjects
by means of lymph node puncture, lymph node dissection,
and/or a sentinel node procedure. In 44 patients, CM had
metastasized to the lymph nodes (i.e., positive), with a
maximum count of 20 positive nodes per patient. Twenty-
nine patients participated in a study, which comprised
research on dendritic cell (DC) vaccinations (n = 18),
observational arm of the DC vaccination study (n = 4),Dermatology Research and Practice 3
Table 1: Descriptive statistics for the ﬁrst cutaneous melanoma (CM 1).
Males n (%) Females n (%) Total n (%)
Tumour invasiveness
In situ 6 (6.7) 15 (14.4) 21 (10.8)
Invasive 75 (83.3) 83 (79.8) 158 (81.4)
Metastasisa 9 (10.0) 6 (5.8) 15 (7.7)
Localization
Head/neck 14 (15.6) 12 (11.5) 26 (13.4)
Trunk 38 (42.4) 40 (38.5) 78 (40.2)
Proximal extremities 10 (11.1) 11 (10.6) 21 (10.8)
Distal extremities 19 (21.1) 35 (33.7) 54 (27.8)
Unknown primary 9 (10.0) 6 (5.8) 15 (7.7)
Histological type
SSMb 54 (60.0) 70 (67.3) 124 (63.9)
NMc 10 (11.1) 6 (5.8) 16 (8.2)
LMMd 5 (5.6) 8 (7.7) 13 (6.7)
ALMe 3 (3.3) 1 (1.0) 4 (2.1)
AMMf 1 (1.1) 1 (1.0) 2 (1.0)
Spitzoid melanoma 1 (1.1) 0 1 (0.5)
STUMPg 1 (1.1) 1 (1.0) 2 (1.0)
Melanoma, not speciﬁed 6 (6.7) 11 (10.6) 17 (8.8)
Unknown primary 9 (10.0) 6 (5.8) 15 (7.7)
Breslow tumour thickness (mm)
<1.01 44 (54.3) 70 (71.4) 114 (63.7)
1.01–2.00 17 (21.0) 18 (18.4) 35 (19.6)
2.01–4.00 11 (13.6) 7 (7.1) 18 (10.1)
>4.00 9 (11.1) 3 (3.1) 12 (6.7)
Clark invasiveness
I 6 (8.5) 15 (17.6) 21 (13.5)
II 20 (28.2) 25 (29.4) 45 (28.8)
III 19 (26.8) 21 (24.7) 40 (25.6)
IV 23 (32.4) 21 (24.7) 44 (28.2)
V 3 (4.2) 3 (3.5) 6 (3.8)
a Unknown primary melanoma; bsuperﬁcial spreading melanoma; cnodular melanoma; dlentigo maligna melanoma; eacral-lentiginous melanoma;
famelanotic malignant melanoma; gspitzoid tumour of unknown malignant potency.
a study with Ganglioside (n = 4), a PEG interferon study
(n = 2),andastudyonTicilimumab(n = 1).Fifteenpatients
in this cohort underwent chemotherapy and 12 palliative
radiotherapy as treatment of their melanoma.
We tried to document and analyse the follow-up of
the patients but failed because each patient seems to have
another follow-up scheme. Some of them asked for a higher
frequency of controls, while others repeatedly did not show
up. Furthermore, various patients had more than one reason
to consult the dermatologist.
3.2. Risk Factors. There are multiple risk factors for
melanoma. We tried to evaluate country of origin, pheno-
type, social class, medication, ultraviolet radiation (UVR)
exposure, immune status, previous radiotherapy and/or
chemotherapy, and life style factors, such as diet and alcohol
use.Informationaboutmostofthesefactorswasincomplete,
because this was not routinely collected. Only the variables
with enough data are mentioned.
According to the dermatologists 26.8% of the patients
h a da ne x c e p t i o n a l l yh i g hc o u n to fn e v ia n d1 0 . 3 %a ne x c e p -
tionally low count. 6.7% had radiotherapy in the past and
1.5% chemotherapy. The number of immune-compromised
patientswassmall(1.5%).Eight(4.1%)patientsreporteduse
of any kind of immunosuppressive medication.
Family history of melanoma was positive in 24 patients
(valid percentage 14.6), negative in 140 (valid percentage
85.4), and unknown in 30. There was no signiﬁcant
diﬀerence between a positive and negative family history
of melanoma with regard to the occurrence of BCC or
noncutaneouscancerinthisstudygroup.Eightpatientscited
the occurrence of intestinal cancer in ﬁrst- and second-
degree relatives, seven patients named lung cancer, and two
cancer of the prostate. Eighteen patients mentioned relatives4 Dermatology Research and Practice
with breast cancer, three ovarian cancer, and three had
relatives with cervical cancer. Two patients mentioned the
occurrence of pancreas carcinoma in third-degree relatives.
Other cancers among relatives were liver cancer, renal cell
cancer, bladder cancer, testis cancer, Hodgkin lymphoma,
leukaemia, and undeﬁned cancers. Two subjects complied
with the deﬁnition of familial type DNS and four had
sporadic type DNS. Three of them requested for genetic
examination, but none of them had the particular gene
mutation.
3.3. Second Primary Tumours. Eleven patients (6.1%) with
a ﬁrst primary melanoma, four males and seven females,
developed a second CM. The average age of the patients
at diagnosis of the subsequent CM was 47.6 years (SD
13.9). In one individual the ﬁrst and the second CM were
simultaneously diagnosed, one at the thorax and the other
at the forearm. The median time interval between the
diagnoses was 13.4 months (range 0–29.2 months). In four
patients the subsequent CM developed within the same
anatomic place, whereas in seven patients they developed
in diﬀerent anatomic places. Median and mean tumour
thicknesses according to Breslow were 0.40mm and 0.49mm
(SD 0.66), respectively. Table 2 describes the characteristics
of the second CM.
In our group of patients 12.4% had one or more basal
cell carcinoma (BCC). Male-female ratio was 15 : 9. We
documented a total of 83 BCCs: 11 patients developed
one BCC, 3 patients developed two, 2 patients three,
and 8 patients four or more BCCs. 68.7% of the BCCs
occurred before the ﬁrst CM, 12.0% simultaneously, and
19.3% after the ﬁrst CM. Mean age at the diagnosis of the
ﬁrst registered BCC was 64.5 years (SD 11.6) (Figure 2).
With respect to histological type, the number of cases was
distributed as follows: superﬁcial 39.8%, nodular 25.3%,
inﬁltrative 4.8%, morphea type 1.2%, and unknown type
9.6%. The remaining 19.3% had a combination of diﬀerent
histologicaltypes.Thetumoursweremostfrequentlylocated
at the trunk (42.2%) and in the head/neck region (43.4%).
Three male patients (1.5%) were diagnosed with squamous
cell carcinoma (SCC). Two patients developed two SCCs
and the other only one. In two patients their ﬁrst SCC
preceded the ﬁrst CM and in one it occurred after the
CM.
Twenty-six primary noncutaneous cancers were identi-
ﬁed in 21 patients (10.8%) (Table 3). Seventeen patients had
noncutaneous cancer diagnosed before CM, three patients
had subsequent cancer after the diagnosis of melanoma,
and date of diagnosis was missing in one patient. Three of
the patients had both melanoma and noncutaneous cancer
diagnosed in the same year.
We calculated the probability for a subsequent primary
tumour (a second primary CM, NMSC and/or noncu-
taneous cancer) by means of the Kaplan-Meier method.
Figure 3 shows the actuarial survival curve representing the
probability of a second primary tumour after the ﬁrst CM.
Data of patients without the event were censored at the date
of the last check of the electronic patient database (1st June
2007) or at their time of death.
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Figure 2: Age of the patients at the time of ﬁrst basal cell carcinoma
diagnosis.
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Figure 3: Actuarial survival curve representing the probability of a
second primarytumour (cutaneous and noncutaneous) in monthly
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Table 2: Descriptive statistics for the second cutaneous melanoma (CM 2).
Males n (%) Females n (%) Total n (%)
Tumour invasiveness
In situ 1 (25.0) 4 (57.1) 5 (45.5)
Invasive 3 (75.0) 3 (42.9) 6 (54.5)
Localization
Head/neck 0 0 0
Trunk 2 (50.0) 3 (42.9) 5 (45.5)
Proximal extremities 1 (25.0) 2 (28.6) 3 (27.3)
Distal extremities 1 (25.0) 2 (28.6) 3 (27.3)
Histological type
SSMa 3 (75.0) 3 (42.9) 6 (54.5)
LMMb 0 1 (14.3) 1 (9.1)
Melanoma, not speciﬁed 1 (25.0) 3 (42.9) 4 (36.4)
Breslow tumour thickness (mm)
<1.01 3 (75.0) 7 (100) 10 (90.9)
1.01–2.00 0 0 0
2.01–4.00 1 (25.0) 0 1 (9.1)
>4.00 0 0 0
Clark invasiveness
I 1 (33.3) 4 (57.1) 5 (50.0)
II 0 1 (14.3) 1 (10.0)
III 2 (66.7) 2 (28.6) 4 (40.0)
IV 0 0 0
V0 0 0
a Superﬁcial spreading melanoma; blentigo maligna melanoma.
Table 3: Observed number of cases of noncutaneous malignancies
in CM patients.
Site Observed number
Both sexes Males Females
Tonsil 1 1 0
Plasmacytoma 2 2 0
Leukaemia 1 1 0
Pancreas 1 0 1
Kidney 2 2 0
Bladder 2 2 0
Lung 3a 3a 0
Breast 7a 2a 5
Cervix 2b —2 b
Prostate 5 5 —
a One tumour in situ, btwo tumours in situ.
4. Discussion
Wecollecteddataon194patientssuﬀeringfromCMinorder
to analyse the clinical characteristics of CM and to deﬁne the
frequency, site, and type of second primary cancers in CM
patients.
The distribution of sex and age of patients with CM
corresponded well with European data [4, 7, 8, 10, 11,
33]. According to literature, anatomical distribution of
melanoma is sex dependent. The most common areas are
the trunk for men and the arms and legs for women [4, 5,
8, 10, 11, 33, 34]. This dissimilarity between the sexes could
be explained by diﬀerences in sun exposure patterns, which
matches diﬀerences in usual clothing patterns and hair cover
[35]. Nevertheless, a recent study stated that in 2004 the
only diﬀerence in site distribution between both sexes was an
increased proportion of head and neck melanomas in men.
Mostcommonareainboth,malesandfemales,wasthetrunk
[36]. In our cohort most CM were located on the trunk, both
in men (42.4%) and women (38.5%), followed by the distal
extremities (21.1% in men; 33.7% in women).
Distribution of histological type of melanoma, median
tumour thickness according to Breslow, and documented
Clark invasiveness corresponded well with previous studies
[4, 8, 10, 11, 33]. Twenty-six percent of the primary
melanomas reviewed by Bevona et al. were histologically
associated with nevi [37]. We found a percentage of 19.6%.
Our ﬁndings with regard to ulceration and regression
corresponded with that of the Central Malignant Melanoma
Registry of the German Dermatological Society [10].
A positive family history of melanoma is considered to
be a strong risk factor for the occurrence of melanoma. The
risk of developing a CM is approximately 2 times higher
in persons with a history of melanoma in a ﬁrst-degree
relative compared to the risk of those without [38–40].
In a study conducted by Tucker et al., the excess risk of
CM in the melanoma-prone families remained restricted
to those participants with prior melanoma or dysplastic6 Dermatology Research and Practice
nevi [41]. According to literature approximately 10% of the
melanoma patients have a positive family history [42]. In
our study 14.6% had a positive history. This diﬀerence can
be explained by the relatively high count of missing values
(15.5%). A family history of noncutaneous cancers could be
a risk factor for melanoma and be a part of a hereditary
cancersyndrome.Bergmanetal.observedasigniﬁcantexcess
of gastrointestinal cancer in nine FAMMM (familial atyp-
ical multiple mole syndrome) families in The Netherlands
[43]. More recent, familial syndromes of melanoma and
tumours of the nervous system [44], breast cancer [45],
and/or pancreatic cancer [45–49]h a v eb e e nd o c u m e n t e d .
Furthermore, melanoma clusters in families with familial
retinoblastoma, Li-Fraumeni cancer syndrome, and Lynch
s y n d r o m et y p eI I[ 42, 50, 51]. In our study the most
frequent cancer among relatives was, as expected on the basis
of above mentioned literature, breast cancer, followed by
intestinal cancer and lung cancer. Just two patients reported
on pancreas carcinoma in third-degree relatives.
Among the 179 primary CM studied, 11 patients (6.1%)
developed a second CM. Previous studies found incidences
rangingfrom2.0%to8.0%[13,15,16,52–54].Inaccordance
withpreviousstudies,ourdataindicatethatmostsubsequent
CM occur within the ﬁrst years after the initial diagnosis
[13, 17, 53, 54]. The latter subscribes the importance of a
follow-upaftertheﬁrstmelanomadiagnosis.Thesubsequent
CM developed in 36.4% of the patients at the same location
as before. Percentages found in other studies varied from
34.1% to 51% [53–55]. SSM was the most frequently found
histological subtype in both the ﬁrst and second CM. This
is consistent with a previous study [52], although Savoia et
al. indicated a higher risk of second CM in patients with the
LMM type [54]. We observed a much higher incidence of
BCC (12.4% with in total 83 BCC) than SCC (1.5% with in
total 5 SCC) in our study cohort. Other studies conducted
in a cohort of cutaneous melanoma patients found a ratio
BCC:SCC between 7 : 1 and 9 : 1 [19, 20, 52]. The ratio
in the overall population varies between 3 : 1 and 8 : 1
[6, 33, 56]. Our results regarding sex and age distribution
correspond well with earlier reports [6, 14, 20, 33, 52, 56].
Most common histological subtypes were superﬁcial and
nodular BCC, which is consistent with another Dutch study
[57]. It is known that BCC typically arise in sun-exposed
regions, like the head and neck [20, 33, 52, 56, 57]. In this
cohort tumours were most frequently located at the trunk,
followed by the head/neck region. The correlation between
NMSC and melanoma risk could be the eﬀect of shared risk
factors, like phenotype and UVR exposure [58–61]. Because
of the retrospective nature of this study and the fact that
the information is not routinely collected, such a hypothesis
cannot be tested. Furthermore, a genetic susceptibility for
skin cancers could explain the coexistence of diﬀerent types
of skin cancers in the same patient.
The current study is hospital based. For that reason,
it cannot be automatically extrapolated to the general
population. However, the clinical data for melanoma are
closely comparable to the existing literature and may thus
be regarded as representative. The considerable number
of missing data is an important limitation in our study,
especially with regard to risk factors. The strength of our
study is the combined use of data from the cancer registries,
patients’ hospital chart and the electronic patient database,
which implies that our data were more detailed than data
from the general cancer registration.
Two possible selection biases should be taken into
account. First, there is an increased surveillance by the
patient and by physician after ﬁrst diagnosis of cancer. This
may lead to early and increased detection of subsequent
malignancies. Second, diﬀerences in the lifestyle (e.g., sun-
bathing habit) of the population in our study and the general
population cannot be excluded and may have inﬂuenced
the results. In addition, most published articles analysed the
occurrence of a second primary malignancy subsequent to
melanoma.Weinvestigatedthecutaneousandnoncutaneous
malignancies occurring either before or after the diagnosis of
CM.
Finally, statistical analyses of the risk of a second primary
tumour in CM patients could not be performed as a conse-
quence of the relatively small number of patients registered.
We recommend to continue this registry to attain a larger
cohort and achieve more statistical power. Furthermore, the
use of a standard oncologic questionnaire by the physician
might improve the quality and quantity of information on
risk factors for CM.
In conclusion, in the present study 48 CM patients
(24.7%) developed a subsequent malignancy. Therefore
it seems feasible to monitor CM patients for signs of
subsequent malignancies. As NMSC is the most frequent
second tumour, our results subscribe to the need of follow-
up by a dermatologist.
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